title: Cannabidiol as a potential treatment for psychosis.
abstract: Although cannabis use is associated with an increased risk of developing psychosis, the cannabis constituent cannabidiol (CBD) may have antipsychotic properties. This review concisely describes the role of the endocannabinoid system in the development of psychosis and provides an overview of currently available animal, human experimental, imaging, epidemiological and clinical studies that investigated the antipsychotic properties of CBD. In this targeted literature review we performed a search for English articles using Medline and EMBASE. Studies were selected if they described experiments with psychosis models, psychotic symptoms or psychotic disorders as outcome measure and involved the use of CBD as intervention. Evidence from several research domains suggests that CBD shows potential for antipsychotic treatment.
authors.affiliation: Tergooi Hospital, Department of Psychiatry, Blaricum, The Netherlands.
authors.forename: C D
authors.initials: CD
authors.lastname: Schubart
authors.affiliation: Brain Center Rudolf Magnus, University Medical Centre Utrecht, Department of Psychiatry, The Netherlands.
authors.forename: I E C
authors.initials: IE
authors.lastname: Sommer
authors.affiliation: Department of Psychosis Studies, Institute of Psychiatry, King's College London, UK.
authors.forename: P
authors.initials: P
authors.lastname: Fusar-Poli
authors.affiliation: Brain Center Rudolf Magnus, University Medical Centre Utrecht, Department of Psychiatry, The Netherlands.
authors.forename: L
authors.initials: L
authors.lastname: de Witte
authors.affiliation: Tergooi Hospital, Department of Psychiatry, Blaricum, The Netherlands.
authors.forename: R S
authors.initials: RS
authors.lastname: Kahn
authors.affiliation: Brain Center Rudolf Magnus, University Medical Centre Utrecht, Department of Psychiatry, The Netherlands. Electronic address: m.p.m.boks@umcutrecht.nl.
authors.forename: M P M
authors.initials: MP
authors.lastname: Boks
mesh_terms: D000818:Animals; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D002185:Cannabidiol / Q000627:therapeutic use*; D016206:Databases, Bibliographic / Q000706:statistics & numerical data; D006801:Humans; D011618:Psychotic Disorders / Q000188:drug therapy*
chemical_list: D014150:Antipsychotic Agents; D002185:Cannabidiol
keywords: Antipsychotics; Cannabidiol; Cannabis; Psychosis; Schizophrenia; Treatment